Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder. Lupus nephritis (LN) is one of the severe clinical implications in SLE, and this was relates to fibrosis in the kidney. As an important marker in the tumor necrosis factor (TNF) superfamily, TNF‐like weak inducer of apoptosis (TWEAK) has been given much attention with respect to its role in regulating pro‐inflammatory immune response. Fibroblast growth factor‐inducible 14 (Fn14), the sole receptor for TWEAK, has been found expressed in different immune and non‐immune cells. TWEAK binds to Fn14, and then regulates inflammatory components production via downstream signaling pathways. To date, dysregulated expression of TWEAK, Fn14 has been reported in SLE, LN patients, and in vivo, in vitro studies have discussed the significant role of TWEAK‐Fn14 axis in SLE, LN pathogenesis, partly through mediating the fibrosis process. In this review, we will discuss the association of TWEAK‐Fn14 axis in lupus. Understanding the relationship will better realize the potential for making TWEAK‐Fn14 as a marker for the diseases, and will help to give many clues for targeting them in treatment of lupus in the future.